Navigation Links
Van Andel Research Institute findings provide more complete picture of kidney cancer
Date:12/29/2011

Grand Rapids, Mich. (December 29, 2011) Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments.

In a study published in Cancer Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, Ph.D., researchers provide a more complete understanding of the biology of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive type of kidney cancer with no effective treatment, which lays the foundation for the development of effective treatment strategies.

Despite obvious morphological, genetic, and clinical differences, hereditary PRCC2 is thought to share similar pathway deregulation due to genetic mutation with its counterpart, clear cell renal cell carcinoma (CCRCC), a subtype that accounts for 75% of all kidney cancers and that, unlike PRCC2, responds favorably to drugs targeting vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate blood vessel formation.

The study, which included international collaboration with researchers from the National Cancer Centre Singapore, Gntique Oncologique EPFE-INSERM U753 and Facult de Mdecine Paris-Sud, Le Kremlin-Bictre and Institut de Cancrologie Gustave Roussy, Michigan State University, Northwestern Memorial Hospital, Cleveland Clinic, Singapore General Hospital, and The Wistar Institute, identified deregulation of the KEAP1-NRF2 signaling pathway as a factor that distinguishes PRCC2 from CCRCC, but links both hereditary and sporadic PRCC2.

In another study published in Cancer Research, led by Yan Ding, Ph.D., and Bin Tean Teh, Ph.D. and carried out in collaboration with the National Cancer Centre Singapore, researchers integrated gene expression profiling and RNAi screening data to identify genes involved in CCRCC development and progression.

In recent years, several molecularly targeted therapies such as sunitinib, sorafenib, and pazopanib, which target the receptor tyrosine kinases of VEGF have been approved for CCRCC. Although these therapies significantly extend overall survival, nearly all patients with advanced CCRCC eventually succumb to the disease.

Gene set enrichment analysis indicated that cell-cycle-related genes, in particular PLK1, were associated with disease aggressiveness. Further, the association of PLK1 in both disease aggression and in vitro growth prompted researchers to examine the effects of a small-molecule inhibitor in CCRCC cell lines. Their findings highlight PLK1 as a promising potential therapeutic target for CCRCC.


'/>"/>

Contact: Joe Gavan
joe.gavan@vai.org
616-234-5390
Van Andel Research Institute
Source:Eurekalert

Related medicine news :

1. Van Andel Institute study may lead to better, safer drug for diabetes
2. Van Andel Research Institute finding could lead to reduced side effects in anti-cancer antibiotics
3. Van Andel Research Institute finding is potential predictor of deadly cancer common in Asia
4. Chairman Al Brandel of Lions Clubs International Foundation to Appear in Washington DC's National Memorial Day Parade
5. AADR awards the 2010 Distinguished Mentoring Award to Irwin D. Mandel
6. Research!America Chair John Edward Porter says health research and prevention fared well in 2011
7. UT Southwestern research suggests new way to ensure effectiveness of TB treatment
8. President Obama and leading GOP presidential candidate support health research
9. Cleveland Clinic researchers honored for contributions to science
10. UK researchers present findings from Kentucky breast cancer patients with disease relapse
11. Pitt researchers propose new model to design better flu shots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... CloudLIMS.com, a class-leading provider of Laboratory Management ... Lite helps biobanks, clinical, research and testing laboratories keep track of their biospecimens, ... is a faster and a more efficient product, allowing batch processing of data, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... imaging systems and the first company to offer robotic imaging to veterinary ... their tradeshow booth # 941 for the American Association of Equine Practitioners 62nd ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ... health, day and night. No other wearable health technology on the market can deliver ... to give poeple more meaningful insights about their health than the usual heart rate ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
(Date:12/2/2016)... ... December 02, 2016 , ... On ... individuals and families from eight different sites throughout Miami-Dade and Broward counties. This ... volunteers worked very hard on Thanksgiving morning by putting together individual meals via ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... GARDENS, N.Y. , Dec. 2, 2016  LifeVac, ... will be included in the Emergency Response Training and ... are very excited to have LifeVac become part of ... Lih , Founder and CEO of LifeVac. "Having an ... LifeVac safely and effectively will help leverage our efforts ...
(Date:12/2/2016)... , Dec. 2, 2016  PipelineRx, a leading medication ... be offering demonstrations of its SaaS-based telepharmacy platform, ... Health-System Pharmacists 2016 Midyear Clinical Meeting and Exhibition, ... . With nearly 300 hospital clients nationally, the ... technology designed to dramatically improve pharmacy operations, enhance ...
(Date:12/2/2016)... AMARILLO, Texas , Dec. 2, 2016  Maxor National ... its acquisition of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... and Georgia -based PSI bring together both ... patients, physicians, manufacturers, and payers an industry-leading specialty pharmacy. ... , ...
Breaking Medicine Technology: